On Monday, Shares of PPG Industries, Inc. (NYSE:PPG), lost -0.47% to $107.87.
PPG Industries, declared the grand opening of PPG PAINTS stores in its global headquarters community of Pittsburgh.
PPG is renovating the 16 stores, which were attained from two independent paint retailers in 2014, to dramatically enhance the customer experience with expanded store footprints, customer-friendly service counters, industry-leading color selection tools and colorful, well-lit interiors. Interior walls are branded with PPG’s signature blue and large colorful stripes that reflect the PPG Paints logo, which also appears on a fleet of 24 delivery vehicles that serve the Pittsburgh area. In-store representatives are accessible to provide painting professionals and do-it-yourself consumers with expert project and product guidance and personalized service. In addition to more than 30 lines of paint and stain products, the stores provide a selection of supplies and equipment such as brushes, paint applicators, spray equipment, caulk and patching materials.
PPG Industries, Inc. manufactures and distributes coatings, specialty materials, and glass products. The company’s Performance Coatings segment provides coatings products for automotive and commercial transport/fleet repair and refurbishing; light industrial and specialty coatings for signs; sealants, coatings, maintenance cleaners, and transparencies for commercial, military, regional jet and general aviation aircraft, and transparent armor for specialty applications; and chemical administration services.
Shares of ImmunoGen, Inc. (NASDAQ:IMGN), declined -7.71% to $16.63, during its last trading session.
ImmunoGen, stated financial results for the Company’s 2015 fiscal year ended June 30, 2015. ImmunoGen also offered an update on product programs and guidance for its 2016 fiscal year.
“This is clearly a transformational year for ImmunoGen,” commented Daniel Junius, President and CEO. “Our lead product candidate, mirvetuximab soravtansine, has demonstrated impressive single-agent activity against platinum-resistant ovarian cancer in early clinical testing, and we are on track to initiate a trial later this year that could potentially support an accelerated registration pathway. We are also preparing to start a separate trial by year end to assess mirvetuximab soravtansine used in combination with other anticancer agents to potentially assist more patients benefit from this promising agent, counting women with earlier-stage disease. We plan to start the clinical assessment of our IMGN529 ADC in combination with rituximab shortly, with combination assessment of our other promising ADC for B-cell malignancies, coltuximab ravtansine, predictable to start in 2016. And we are on track to submit an IND this fall for our next novel anticancer agent, IMGN779, which utilizes one of our potent new IGN payload agents.”
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
At the end of Monday’s trade, Shares of McKesson Corporation (NYSE:MCK), gained 1.32% to $223.48.
ArcBest Corporation, declared two new members to the Board of Directors, Kathy D. McElligott and Stephen E. Gorman, effective July 28.
The two new directors bring the total board membership of ArcBest to 11 from nine formerly.
“Both Kathy and Steve bring tremendous experience and credentials to our board,” said ArcBest President and CEO Judy R. McReynolds. “Kathy’s vast experience in the administration of information technology and supply chain, together with Steve’s deep background in operations and transportation administration, will serve us well as we expertly solve our customers’ complex supply chain needs. I’m confident that Kathy’s and Steve’s skills, expertise and insights will provide value to our company.”
Ms. McElligott, 59, is Executive Vice President and Chief Information and Technology Officer of McKesson Corp. (MCK), a healthcare services and information technology company based in San Francisco and the largest pharmaceutical distributor in North America. She joined McKesson on July 20, 2015, after serving as the Chief Information Officer and Vice President, Information Technology at Emerson Electric Co. since 2010. Preceding to joining Emerson, she spent 22 years with General Electric Company in multiple information systems leadership roles, counting CIO of supply chain at GE Aircraft Engines. She holds a bachelor’s degree in computer science from Kent State University and a MBA from Xavier University. She is former board president of Connections to Success, a St. Louis-based nonprofit organization.
McKesson Corporation delivers pharmaceuticals, medical supplies, and health care information technologies to the healthcare industry in the United States and internationally.
Finally, USG Corporation (NYSE:USG), ended its last trade with -1.68% loss, and closed at $ 30.46.
USG Corporation, stated results for the second quarter of 2015. “All of our businesses expanded their margins and contributed to our strong second quarter,” said James S. Metcalf, Chairman, President, and CEO. “We generated the highest level of net income since the fourth quarter of 2006 when demand was fifty percent higher.”
On a merged basis in the second quarter of 2015, net sales were $970 million, up 2 percent from the second quarter of 2014. Operating profit improved 7 percent to $105 million. The corporation’s adjusted operating profit was $118 million in the second quarter of 2015, contrast to an adjusted operating profit of $87 million in the second quarter of 2014.
USG Corporation, through its auxiliaries, operates as a manufacturer and distributor of building materials worldwide. Its Gypsum segment provides gypsum and related products that are used to construct walls, ceilings, roofs, and floors of residential, commercial, and institutional buildings, in addition to in various industrial applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
